Anavip
ANAVIP is the trade name of a snake antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.[1][2][3] As defined by the FDA, the proper name is crotalidae immune F(ab')2 (equine).[4] It is manufactured by Instituto Bioclon for Rare Disease Therapeutics in the United States.
ANAVIP is a divalent fragment antigen-binding protein, F(ab')2, derived from the blood of horses immunized with the venom of the snakes Bothrops asper and Crotalus durissus. The product is produced by pepsin digestion of horse blood plasma then purified resulting in a preparation containing >85% F(ab')2.[5]
References
- ^ Cocchio, Craig; Johnson, Jami; Clifton, Shari (2020-01-24). "Review of North American pit viper antivenoms". American Journal of Health-System Pharmacy. 77 (3): 175–187. doi:10.1093/ajhp/zxz278. ISSN 1535-2900. PMID 31974558.
- ^ "Marketing authorization with orphan designation - USA". orpha.net. orphanet. Retrieved 19 August 2020.
- ^ "Highlights of Prescribing Information". U.S. Food & Drug Administration.
{{cite web}}: CS1 maint: url-status (link) - ^ Research, Center for Biologics Evaluation and (2019-10-02). "ANAVIP". FDA.
- ^ Laboratorios Silanes S.A. de C.V. "Highlights of Prescribing Information" (PDF). Package_Insert. Retrieved 18 August 2020.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |